A randomized double-blind controlled clinical study of Qiangxin compound in the treatment of type 2 cardiorenal syndrome under the hierarchical management mode of Integrated Chinese and Western Medicine
Phase 1
- Conditions
- type 2 cardiorenal syndrome
- Registration Number
- ITMCTR2000003812
- Lead Sponsor
- Traditional Chinese Medicine Hospital of Shanghai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Heart failure stage C, D, heart function II to III with mild to severe renal insufficiency.
Exclusion Criteria
1. Patients with renal insufficiency caused by non cardiac causes;
2. Pregnant or lactating women, allergic constitution and allergic to a variety of drugs;
3. Combined with severe liver insufficiency and endocrine system, hematopoietic system and other serious primary diseases;
4. Those with mental disorder and unwilling to cooperate;
5. The factors that can increase the mortality rate include cardiogenic shock, severe ventricular arrhythmia, complete atrioventricular block and obvious infection;
6. Creatinine clearance rate < 15% of patients requiring dialysis;
7. History of cardiac surgery.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Minnesota Heart Failure Quality of life questionnaire;6-minute walk test;Heart failure symptom rating scale;
- Secondary Outcome Measures
Name Time Method Alanine aminotransferase;Serum creatinine;total bilirubin;Cystatin C;Aspartate aminotransferase;Urinary microprotein;brain natriuretic peptide;